Evotec opens the week with sector comparison, shares in SDAX biotech context
26.06.2026 - 09:24:00 | ad-hoc-news.de
By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 09:23.
Evotec SE (DE0005664809) starts the new trading week as a member of Germany’s SDAX and TecDAX indices in the Prime Standard segment of Deutsche Börse, with its shares trading on Xetra in the biotechnology peer group. The stock’s recent performance offers a muted picture against selected European and US biotech names, giving retail investors a concrete sector yardstick.
Evotec in the German biotech cluster
Evotec positions itself within the German-listed biotech universe that includes peers such as Morphosys and BioNTech’s US listing, while the company’s shares remain tied to the SDAX and TecDAX benchmarks on Xetra. Sector classification on many data providers places Evotec in biotechnology, closely compared to drug discovery and contract research groups.
The Prime Standard segment of Deutsche Börse requires strict reporting and transparency obligations, which Evotec adheres to via regular disclosures and an investor relations presence. This listing environment allows investors to benchmark Evotec against other German mid-cap growth names in technology-driven industries, including software and medical technology groups in the TecDAX.
How Evotec shares have moved recently
Recent indicative price data for Evotec on Frankfurt-based platforms show the shares trading below 5 euros, with intraday levels around 4.75 to 4.83 euros in late June, reflecting a compressed valuation compared with historic highs. These prints place the company toward the lower end of its 12-month range, highlighting the cautious sentiment that has weighed on many European biotech names.
The one-year chart on price services such as Finanznachrichten.de shows that Evotec shares have experienced pronounced volatility, with significant declines from earlier peaks as investor focus shifted to larger, more profitable pharma and biotech names. In the five-day chart, the share price pattern appears relatively flat, mirroring a broader consolidation in German small-cap growth stocks amid mixed macroeconomic signals.
All news and data on the Evotec shares
Further company disclosures, price data and SDAX / TecDAX context for Evotec can be found on ad-hoc-news.de and the group’s own investor relations pages.
The business behind Evotec’s revenues
Evotec’s core business model combines fee-for-service research and development work with risk-sharing agreements and proprietary pipeline development, focusing on early-stage drug discovery collaborations with pharmaceutical and biotech partners. The company is known for integrated discovery platforms, including medicinal chemistry, screening technologies and preclinical development services that underpin multi-year partnerships.
Representative activities include integrated drug discovery alliances across therapeutic areas such as neurology, metabolic diseases and oncology, where Evotec contributes target identification, lead optimization and translational biology capabilities. Revenue streams typically mix milestone payments, research funding and potential success-based royalties from partnered programs, providing exposure to long-term upside when candidates progress into clinical stages.
Where Evotec shares trade today
Evotec shares (DE0005664809) trade on Xetra as part of the SDAX and TecDAX, with recent indicative prices around 4.75 to 4.83 euros and low double-digit million euros in market capitalization on late June readings. These values place the stock among the smaller constituents of Germany’s listed biotech universe.
Key data on the Evotec shares
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVT
- Trading venue: Xetra
- Price (as of 2026-06-25, 17:35): 4.84 euros
- Market cap: 0.7 billion euros (as of 2026-06-25)
- Sector / industry: Biotechnology
- Index membership: SDAX, TecDAX
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any form of financial promotion. All data are based on sources believed to be reliable but may be subject to revision. Investors should conduct their own research or consult a qualified advisor before making investment decisions.
